Journal article
The N3RO trial: A randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants <29 weeks' gestation
CT Collins, RA Gibson, M Makrides, AJ McPhee, TR Sullivan, PG Davis, M Thio, K Simmer, VS Rajadurai, P Ryan, S Morris, M Stark, J Travadi, I Wright, K Tan, J Holberton, G Opie, I Callander, J Stack, D Shein Show all
BMC Pediatrics | BIOMED CENTRAL LTD | Published : 2016
Abstract
Background: Bronchopulmonary dysplasia (BPD) is a major cause of mortality and long-term respiratory and neurological morbidity in very preterm infants. While survival rates of very preterm infants have increased over the past two decades there has been no decrease in the rate of BPD in surviving infants. Evidence from animal and human studies has suggested potential benefits of docosahexaenoic acid (DHA), an n-3 long chain polyunsaturated fatty acid, in the prevention of chronic lung disease. This randomised controlled trial aims to determine the effectiveness of supplementary DHA in reducing the rate of BPD in infants less than 29 weeks' gestation. Methods/design: This is a multicentre, pa..
View full abstractRelated Projects (1)
Grants
Awarded by Nestlé Nutrition Institute
Funding Acknowledgements
Supported by Project Grant 1022112 from the NHMRC, Australia. Study product is donated by Clover Corporation Limited, Australia. CTC is supported by a MS McLeod Research Fellowship (MS McLeod Research Fund, Women's and Children's Hospital Research Foundation); NHMRC Fellowships support RAG (Senior Principal Research Fellow 1046207), MM (Principal Research Fellow 1061704), PGD (Practitioner Fellow 1059111). The funding bodies had no role in the design of this study and will not have any role during the conduct of the study, data collection, study management, analyses and interpretation of the data or in the writing, review or approval publications. The contents of the published material are solely the responsibility of the authors and do not reflect the views of the NHMRC.